An Alzheimer's Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? [Yahoo! Finance]
vTv Therapeutics Inc. - Class A (VTVT)
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vtvtherapeutics.com
Company Research
Source: Yahoo! Finance
VTVT has surged 182% over the past year, hitting a two-year high, with strong technical momentum. Wall Street leans “Strong Buy” with targets up to $47, but some advisors are more cautious. VTVT is a speculative, technically driven play with fundamentals highly uncertain due to all its revenue and earnings hinging on unproven pipeline assets. Valued at $156 million, vTv Therapeutics (VTVT) is a biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimer's disease is azeliragon TTP488, which is in Phase 3 clinical trials, and it has other candidates for Type 1 and Type 2 diabetes, cancers, psoriasis, and COPD, among others. Tesla Stock Has Been Flat For 2 Months - How to Make a 3.2% Yield in One-Month Puts CES 2026, Sector Rotation and Other Key Things to Watch this Week Why Wall Street Expects This Growth Stock to Soar 84% in 2026
Show less
Read more
Impact Snapshot
Event Time:
VTVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTVT alerts
High impacting vTv Therapeutics Inc. - Class A news events
Weekly update
A roundup of the hottest topics
VTVT
News
- vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at TD Cowen. They set a "buy" rating and a $67.00 price target on the stock.MarketBeat
- vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.MarketBeat
- vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VTVT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
VTVT
Earnings
- 5/15/25 - Miss
VTVT
Sec Filings
- 12/19/25 - Form 8-K
- 12/9/25 - Form SCHEDULE
- 11/25/25 - Form EFFECT
- VTVT's page on the SEC website